



## PerkinElmer Expands Cell-Based Assay Portfolio

WALTHAM - PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, today announced the release of six new AlphaScreen® SureFire® assays for the rapid detection of full-length kinase activation in cell lysates and complex sample types. The six new assays can be utilized for measuring kinasemediated inflammatory and immune responses, as well as cellular growth and cytotoxicity. PerkinElmer's AlphaScreen® SureFire® platform allows for detection of activated kinases by immunosandwich capture of endogenous phosphorylated substrate in cell lysates following treatment of cells with inhibitors and/or activators of signaling pathways.

The AlphaScreen® SureFire® technology may be used in lab-based or drug discovery campaigns and provides a single assay format that is well-suited for use in high-throughput screening (HTS) and lead optimization studies aimed at identifying novel kinase inhibitors. It is the only available no-wash cell-based kinase assay.

The six new assays increase the total number of available AlphaScreen® SureFire® kits to 28. The new assays are used for detection of inflammation, cell growth and cell death, and include:

- Phospho-Caspase 9 (Ser196)
- Phospho-NF- $\kappa$ B p65 (Ser536)
- Phospho-mTOR (Ser2481)
- Phospho-I $\kappa$ B $\alpha$  (Ser32/Ser36)
- Phospho-IKK $\alpha$  (Ser176/Ser180)
- Phospho-IKK $\beta$  (Ser177/Ser181)

“We are delighted to announce the release of the six new assays for the AlphaScreen® SureFire® platform, to assist researchers in maximizing their high-throughput and secondary screening,” said Dr. Richard M. Eglon, president, Biodiscovery, PerkinElmer LAS. “These new additions to the AlphaScreen® SureFire® line of assays – now totaling 28 – are optimal functional cell-based kinase assays for screening of serine/threonine kinases (STKs), receptor tyrosine kinases (RTKs), growth factor and cytokine receptors, signaling pathways and individual cellular kinase targets.”

AlphaScreen® technology is ideally suited for developing non-radioactive, homogeneous assays for the direct measurement of phosphorylated peptides and full-length protein substrates, with no wash step required. AlphaScreen® SureFire®'s ability to measure large protein substrates makes it perfect for application to cellular kinase assays. The SureFire® detection reagents are developed by TGR BioSciences, Ltd., and exclusively distributed by PerkinElmer.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through [www.perkinelmer.com](http://www.perkinelmer.com) or 1-877-PKI-NYSE.

SureFire is a registered trademark of TGR BioSciences, Ltd.

For further information regarding PerkinElmer, please contact:

Media Contact:  
Lauren L. Brennan  
PerkinElmer, Inc.  
(781) 663-5527